Covalon Technologies Ltd.
🇨🇦XTSX.COVCanadaHealthcare
PriceCA$1.950.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 0
- Medium: 0
- Low: 0
EV/EBITDA: below the 1st percentile of its industry and country peers
EV/sales: below the 1st percentile of its industry and country peers
Cash conversion cycle: above the 90th percentile of its industry and country peers
Current ratio: above the 90th percentile of its industry and country peers
Interest coverage: above the 90th percentile of its industry and country peers
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- TSX Venture Exchange . XTSX
- Type
- Stock
- ISIN
- CA22282D3022
- CUSIP
- 22282D302
Company
- Employees
- 0
- Headquarters
- Mississauga, Canada
- Website
- https://www.covalon.com
Market
- Shares outstanding
- 27.6M
- Market cap
- CA$53.47M
Highlights
- Market cap
- CA$53.47M
- EPS LTM
- CA$0.08calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- 23.29calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$32.99M+13%up year on year
- Net income
- CA$2.31M+380.86%up year on year
- Gross margin
- 55.68%+0.94%up year on year
- Free cash flow
- CA$4.39M+586.27%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Covalon Technologies Ltd. is a company in the healthcare sector, listed on TSX Venture Exchange (Canada) under the ticker COV. Its market capitalisation is CA$53.47M, from 27.6M shares outstanding, as of . Across the 141 trading sessions to the shares traded between CA$1.55 and CA$2.38, and the last close of CA$1.95 sits 48% of the way up that range. The company is headquartered in Mississauga, Canada.
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard brand names. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. was incorporated in 2004 and is headquartered in Mississauga, Canada.